Goodwin partner Elaine Herrmann Blais, who focuses her practice on intellectual property litigation and particularly with respect to patent litigation for the life sciences industry, participated in a virtual panel discussion around the considerable commercial hurdles that biosimilars face from both an antitrust and patent perspective. Read the published commentary here.